Pharmacokinetics of α1-antitrypsin replacement therapy in severe congenital emphysema;Farmacocinética de la alfa-1-antitripsina utilizada en el tratamiento sustitutivo del enfisema congénito grave

Archivos de Bronconeumologia

Volumn 42, Issue 10, 2006, Pages 553-556

  Vidal Pla, Rafael ^a   Padullés Zamora, Núria ^a   Sala Piñol, Ferran ^a   Jardí Margaleff, Rosendo ^a   Rodríguez Frías, Francisco ^a   Montoro Ronsano, José Bruno ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Duration of protection; Emphysema; Pharmacokinetics; Replacement therapy; 1 antitrypsin

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; EMPHYSEMA; FEMALE; GENETIC DISORDER; HUMAN; MALE; PRACTICE GUIDELINE; SUBSTITUTION THERAPY;

EID: 33751067225     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093399     Document Type: Article

References (20)

1. Stoller J. Key current clinical issues in alpha-1-antitrypsin deficiency. Respir Care. 2003;48:1216-21.
2. Sandhaus R. Alpha-1- antitrypsin deficiency 6: new and emerging treatments for alpha-1-antitrypsin deficiency. Thorax. 2004;59:904-9.
3. Anonymous. American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900.
4. Stoller JK, Aboussouan LS. Alpha-1-antitrypsin deficiency 5: intravenous augmentation therapy: current understanding. Thorax. 2004;59:708-12.
5. Miravitlles M, Vidal R, Barros-Tizón JC, Bustamente A, España PP, Casas F, et al. Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir Med. 1998;92:1181-7.
6. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988;84:13-31.
7. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316:1055-62.
8. Wewers MD, Casolano MA, Sellers SE, et al. Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316:1055-62.
9. Stoller JK, Fallat R, Schluchter MD, O'Brian RG, Connor JT, Gross N, et al. Augmentation therapy with alpha-1-antitrypsin: patterns of use and adverse events. Chest. 2003;123:1425-34.
10. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety on monthly augmentation therapy for alpha-1-antitrypsin deficiency. JAMA. 1988;260:1259-64.
11. Miravitlles M, Vidai R, Barros-Tirón JC, Bustamante A, España PP, Casas F, et al. Estado actual del tratamiento sustitutivo en el enfisema congénito por déficit de alfa-1-antitripsina. Informe del Registre Nacional. Arch Bronconeumol. 1999;35:446-54.
12. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV́ decline in individuals with severe deficiency of alpha-1-antitrypsin. Am J Resp Crit Care Med. 1998;158:49-59.
13. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha-1-antitrypsin deficiency-related pulmonary emphysema with human alpha-1-antitrypsin. Eur Respir J. 1998;11:428-33.
14. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison D, Ulrik C, et al. A randomized clinical trial of alpha-1-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160:1468-72.
15. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency. Chest. 2000;118:1480-5.
16. Wenchker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha-1-antitrypsin protease inhibitor deficiency before and during therapy with IV alpha-1-protease inhibitor. Chest. 2001;119:737-44.
17. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, et al. Does alpha-1-antitrypsin therapy slow the annual decline in FEV́ in patients with severe hereditary alpha-1-antitrypsin deficiency? Eur Respir J. 1997;10:2260-3.
18. Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha-1-antitrypsin infusion in alpha-1-antitryspin deficiency. Chest. 1997;112:607-13.
19. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165:1494-8.
20. Hubbard RC, Crystal RG. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med. 1988;84:52-62.